RayKnowChina Research Map
Shortlist0

GuangzhouSun Yat-sen University

Sun Yat-sen Memorial Hospital

中山大学孙逸仙纪念医院

Listed for 22 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Sun Yat-sen Memorial Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌25 papers led5 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led2 open trials led
  3. Hepatocellular carcinoma肝细胞癌66 papers led10 open trials led
  4. Stomach cancer胃癌11 papers led5 open trials led
  5. Hepatoblastoma肝母细胞瘤2 papers led
  6. Osteosarcoma骨肉瘤6 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Neuroblastoma神经母细胞瘤8 papers led1 open trial led
  9. Ewing sarcoma尤文肉瘤2 papers led
  10. Multiple myeloma多发性骨髓瘤1 paper led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症4 papers led
  13. Beta thalassaemiaβ 地中海贫血6 papers led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led1 open trial led
  15. IgG4-related diseaseIgG4相关性疾病4 papers led
  16. Hepatic echinococcosis肝包虫病1 paper led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  18. Behçet disease白塞病1 paper led
  19. IgA nephropathyIgA 肾病7 papers led
  20. Osteogenesis imperfecta成骨不全症0 papers led
  21. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  22. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led

Not listed for: Retinoblastoma, Chordoma, Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 25 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
14
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 6620222023: 5520232024: 6620242025: 442025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07705243

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  2. Recruiting
    Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07706985

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  3. Recruiting
    Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06438627

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  4. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

  5. Recruiting
    Deep Learning-based sbORN Diagnostic Model
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06463392

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  6. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  8. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseInduction / concurrent chemotherapySide effects & quality of life
Departments in papersENT / head & neck surgeryNeurologyMedical oncologyOphthalmology / neuro-ophthalmology
Papers it led25
  1. The role of the CTBP2 mediated glycolytic pathway in nasopharyngeal carcinoma metastasis.2026Biochemical and biophysical research communications
  2. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.2026British journal of cancerFree full text
  3. Efficacy and safety of low-dose vs medium-dose bevacizumab for radiation-induced brain necrosis in nasopharyngeal carcinoma survivors.2026Neurological research
  4. Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.2025BMC medicineFree full text
  5. Development and Validation of a Nomogram Model for Predicting Non-keratinizing Nasopharyngeal Carcinoma by Combining Sex and Three EB Virus Antibodies.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  6. Longitudinal observation of radiation-induced cognitive impairment and emotional dysfunction: Based on animal model and clinical cohort.2025Neuroscience
  7. The m6A reader YTHDF1 facilitates nasopharyngeal carcinoma proliferation and migration via c-MYC.2025The Journal of biological chemistryFree full text
  8. Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.2024Clinical and translational medicineFree full text
  9. IgG4-related disease with nasopharyngeal malignancy-like manifestations.2024Frontiers in immunologyFree full text
  10. Targeting Cancer Mitochondria by Inducing an Abnormal Mitochondrial Unfolded Protein Response Leads to Tumor Suppression.2024International journal of medical sciencesFree full text
  11. Age-specific characteristics of head and neck second primary malignancies in patients treated for nasopharyngeal carcinoma: a retrospective study.2024International journal of oral and maxillofacial surgery
  12. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation.2024PLoS pathogensFree full text
  13. Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. A collision tumor of nasopharyngeal carcinoma and primary mantle cell lymphoma in the nasopharynx: a case report and review of the literature.2023BMC oral healthFree full text
  15. Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.2023Frontiers in immunologyFree full text
  16. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.2023Head & neck
  17. C2orf48 promotes the progression of nasopharyngeal carcinoma by regulating high mobility group AT-hook 2.2023Medical oncology (Northwood, London, England)
  18. A radiomics model for predicting the response to methylprednisolone in brain necrosis after radiotherapy for nasopharyngeal carcinoma.2023Radiation oncology (London, England)Free full text
  19. Progression and postoperative complications of osteoradionecrosis of the jaw: a 20-year retrospective study of 124 non-nasopharyngeal cancer cases and meta-analysis.2022BMC oral healthFree full text
  20. Establishment and Validation of a Predictive Model for Radiation-Associated Aspiration Pneumonia in Patients with Radiation-Induced Dysphagia after Nasopharyngeal Carcinoma.2022Behavioural neurologyRCTFree full text
  21. Radiotherapy-Related Neurologic Complications in Patients with Nasopharyngeal Carcinoma: A Multicenter Epidemiologic Study in Southern China.2022Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  22. Nogo-B promotes invasion and metastasis of nasopharyngeal carcinoma via RhoA-SRF-MRTFA pathway.2022Cell death & diseaseFree full text
  23. Radiation optic neuropathy diagnosis in nasopharyngeal carcinoma patients with radiation encephalopathy.2022European journal of ophthalmology
  24. STRESS granule-associated RNA-binding protein CAPRIN1 drives cancer progression and regulates treatment response in nasopharyngeal carcinoma.2022Medical oncology (Northwood, London, England)Free full text
  25. En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck.2021International journal of oral and maxillofacial surgery
Chinese-language papers (not in the count)2
  1. [IgG4-related disease with nasopharyngeal malignancy-like manifestations].2022Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  2. [Transoral robotic nasopharyngectomy for local recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status19
  1. Deep Learning-based sbORN Diagnostic ModelRecruitingNCT06463392Lead sponsorStart 2024-07
  2. Distribution of Bacteria in OME After Radiotherapy For NPC.Status unknownNCT06523933Lead sponsorStart 2024-05
  3. A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPCStatus unknownNCT05949749Lead sponsorStart 2023-08
  4. A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPCStatus unknownNCT05449184Lead sponsorN/AStart 2022-06
  5. Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid StenosisSuspendedNCT02022293Lead sponsorPhase 2Start 2017-01
  6. Treatment of Bevacizumab Followed by Steroid in RNStatus unknownNCT04553510Lead sponsorPhase 2Start 2016-01
  7. Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal CarcinomaCompletedNCT01621880Lead sponsorPhase 2Start 2012-06
  8. Effect of Edaravone on Radiation-induced Temporal Lobe NecrosisCompletedNCT01865201Lead sponsorPhase 2Start 2009-03
  9. Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07706985Lead (inferred)Phase 3Start 2026-07
  10. Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal CarcinomaRecruitingNCT07705243Lead (inferred)Phase 3Start 2026-07
  11. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Lead (inferred)Phase 2Start 2024-06
  12. Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 TrialRecruitingNCT06438627Lead (inferred)Phase 3Start 2024-05
  13. Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyCompletedNCT03906058Lead (inferred)Phase 2Start 2019-04
  14. Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT03708822Lead (inferred)Phase 2Start 2018-10
  15. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  16. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  17. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  18. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  19. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
More papers found outside PubMed (not counted)38
  1. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncologyarticle
  2. 434 Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study2025Journal for ImmunoTherapy of Cancerconference-abstract
  3. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  4. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  5. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  6. AI-Enhanced Automated Planning System for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma: Development and Prospective Clinical Validation2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  8. Development and Performance Evaluation of an LLM-Based Automated Recommendation System for Radiotherapy Treatment Planning2025International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.2025Journal of Clinical Oncologyconference-abstract
  10. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)article
  11. Prior Knowledge-Guided Deep Learning Segmentation Algorithm for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  12. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncologyconference-abstract
  13. WITHDRAWN: 1386P A deep learning-based time-habitat longitudinal MRI radiomics model for predicting short-term treatment outcomes in locally advanced nasopharyngeal carcinoma: A multi-center study2025Annals of Oncologyretraction
  14. 893P Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial2024Annals of Oncologyarticle
  15. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncologyconference-abstract
  16. Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial2024Research Squarepreprint
  17. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)preprint
  18. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  19. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  20. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  21. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.2023Journal of Clinical Oncologyconference-abstract
  22. Enhanced radiosensitivity and chemoradiation efficacy in nasopharyngeal carcinoma via a dual-targeted SPION@polymer hybrid nanosensitizer2023NPG Asia Materialsarticle
  23. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  24. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  25. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  26. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figsharedataset
  27. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  28. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  29. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  30. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  31. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  32. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  33. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  34. Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.2022Journal of Clinical Oncologyconference-abstract
  35. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncologyconference-abstract
  36. Voxel-based radiomics outlines spatial heterogeneity of cerebral radiation necrosis (RN) associated with bevacizumab (Bev) response in head and neck radiotherapy (RT) patients.2022Journal of Clinical Oncologyconference-abstract
  37. Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.2021Journal of Clinical Oncologyconference-abstract
  38. Contouring Methods and Atlas of Organs at Risk2021Practical guides in radiation oncologybook-chapter

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 3320242025: 222025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07595770

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  2. Recruiting
    Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06339619

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryNeoadjuvant & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led10
  1. Right versus left thoracic approach esophagectomy for patients with neoadjuvant immunochemotherapy.2025Annals of medicineFree full text
  2. Single-Cell RNA-Seq Reveals the Effect of Commensal Bacteria on the Multistep Development of Esophageal Cancer.2025Cancer scienceFree full text
  3. Nomograms for predicting the prognosis in multiple primary esophageal squamous cell carcinoma.2024Annals of medicineFree full text
  4. Single-cell RNA sequencing reveals the MIF-ACKR3 receptor-ligand interaction between iCAFs and tumor cells in esophageal squamous cell carcinoma.2024Cellular signalling
  5. CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.2024Journal of experimental & clinical cancer research : CRFree full text
  6. A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/ERK signaling.2023Cell death & diseaseFree full text
  7. Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients.2023Frontiers in cellular and infection microbiologyFree full text
  8. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.2023Journal of surgical oncology
  9. HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma.2022Cell death & diseaseFree full text
  10. Organoid models combined with genome engineering and epigenome studies to define SOX2 function evolution in esophageal squamous cell carcinoma.2021Thoracic cancerFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT07595770Lead sponsorPhase 2Start 2026-05
  2. Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Lead sponsorPhase 2Start 2024-03
More papers found outside PubMed (not counted)8
  1. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  2. Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  3. Identification lymph node metastasis in esophageal squamous cell carcinoma using whole slide images and a hybrid network of multiple instance and transfer learning2023Biomedical Signal Processing and Controlarticle
  4. 359. INTRATUMORAL MICROBIOME IMPACTS IMMUNE INFILTRATES IN TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS2022Diseases of the Esophagusarticle
  5. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  6. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figsharedataset
  7. Genomic profiling of Chinese esophageal squamous cell carcinoma patients and difference of genomic mutation between Chinese and American cohorts.2021Journal of Clinical Oncologyconference-abstract
  8. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 66 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
66
2021–2025
Trials led
18
any status, ClinicalTrials.gov
Open trials led
10
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 8820212022: 8820222023: 121220232024: 191920242025: 18182025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07658833

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  2. Recruiting
    Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07267806

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  3. Recruiting
    Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07806292

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  4. Recruiting
    Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06581315

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  5. Recruiting
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06607107

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  6. Recruiting
    Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05475613

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  7. Recruiting
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT06172205

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  8. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  9. Not yet recruiting
    FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Registry
    NCT06409637

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  10. Not yet recruiting
    Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06749678

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  11. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  12. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  13. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led66
  1. Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T-Cell-Driven Cancer Cell Pyroptosis.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. m6A-Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. TMEM88 modulates the proliferation and metastasis of HCC via the GSK-3β/β-catenin pathway.2025BMC cancerFree full text
  4. Multiparametric dual-energy computed tomography radiomics for predicting microvascular invasion in hepatocellular carcinoma.2025BMC medical imagingFree full text
  5. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.2025Cancer letters
  6. RPL35A Downregulation Suppresses Hepatocellular Carcinoma Cell Proliferation via NCAPG2 Inactivation.2025Cancer medicineFree full text
  7. LncRNA AFAP1-AS1 promoting residual tumor progression after insufficient radiofrequency ablation by up-regulating macropinocytosis in hepatocellular carcinoma.2025Cellular signalling
  8. Post-transarterial chemoembolization hypoxia-induced HIF-1α/WNT/β-catenin signaling promotes hepatocellular carcinoma progression via programed death ligand 1 upregulation.2025Clinical and experimental immunology
  9. Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  10. G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  11. Unveiling B7/CD28 family proteins in hepatocellular carcinoma: insights into communication and prognostic significance.2025Frontiers in immunologyFree full text
  12. Ribonuclease P/MRP subunit RPP40 coordinates the transcription of pre-rRNA and ribosomal protein genes to promote Hepatocellular carcinoma malignancy.2025Gene
  13. Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy.2025International journal of nanomedicineFree full text
  14. A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study.2025International journal of surgery (London, England)Free full text
  15. Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis.2025Molecular cancerFree full text
  16. Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.2025Oncology researchFree full text
  17. Analysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers.2025PeerJFree full text
  18. Safety and efficacy of laparoscopic portal territory fluorescence navigation-guided anatomical liver resection in hepatocellular carcinoma patients.2025Surgical endoscopy
  19. MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.2025Toxicological sciences : an official journal of the Society of ToxicologyFree full text
  20. A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells.2024Advanced healthcare materials
  21. The Taping Game for the Complex G8 Glissonean Approach Is the Most Effective Technique for Laparoscopic Anatomic S8 Resection of Dandelion-Patterned Hepatic Pedicles.2024Annals of surgical oncology
  22. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell death
  23. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.2024British journal of hospital medicine (London, England : 2005)
  24. Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.2024Cancer immunology, immunotherapy : CIIFree full text
  25. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.2024Cancer scienceFree full text
  26. CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.2024Cell death & diseaseFree full text
  27. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  28. Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  29. Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies.2024Clinical and experimental medicineFree full text
  30. Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  31. Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma.2024Computational biology and chemistry
  32. Applying image features of proximal paracancerous tissues in predicting prognosis of patients with hepatocellular carcinoma.2024Computers in biology and medicine
  33. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent.2024Current pharmaceutical design
  34. Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.2024GenesFree full text
  35. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.2024Journal for immunotherapy of cancerFree full text
  36. Hepatitis B Virus X Protein Represses Expression of Tumor Suppressor PTPN18 in Hepatocellular Carcinoma.2024Molecular cancer research : MCR
  37. Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway.2024Naunyn-Schmiedeberg's archives of pharmacology
  38. Downstaging of Hepatocellular Carcinoma Before Liver Transplantation: Current Advances in Selection Criteria and Therapeutic Options.2024Transplantation proceedings
  39. Exploring the efficacy of 18F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation.2023Abdominal radiology (New York)Free full text
  40. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.2023Acta biomaterialia
  41. Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  42. Development and validation of web-based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database.2023Cancer medicineFree full text
  43. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma based on B-Mode US and CEUS.2023European radiology
  44. HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  45. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.2023Journal of advanced researchFree full text
  46. Integrative analysis of lactylation-related genes and establishment of a novel prognostic signature for hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  47. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.2023Journal of gastroenterology and hepatology
  48. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  49. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.2023Nature communicationsFree full text
  50. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.2023The Journal of clinical investigationFree full text
  51. Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  52. CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.2022Cell death & diseaseFree full text
  53. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.2022Digestive diseases and sciences
  54. p62 Promotes Malignancy of Hepatocellular Carcinoma by Regulating the Secretion of Exosomes and the Localization of β-Catenin.2022Frontiers in bioscience (Landmark edition)
  55. A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  56. INPP5F translocates into cytoplasm and interacts with ASPH to promote tumor growth in hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  57. Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.2022Oncogene
  58. Utility of Sonazoid-Enhanced Ultrasound for the Macroscopic Classification of Hepatocellular Carcinoma: A Meta-analysis.2022Ultrasound in medicine & biology
  59. Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development.2021Cell death & diseaseFree full text
  60. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.2021Cell death & diseaseFree full text
  61. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.2021Hepatology international
  62. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.2021OncogeneFree full text
  63. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.2021Oxidative medicine and cellular longevityFree full text
  64. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.2021RNA biologyFree full text
  65. Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma.2021Science progressFree full text
  66. Totally laparoscopic anatomic S7 segmentectomy using in situ split along the right intersectoral and intersegmental planes.2021Surgical endoscopy
Chinese-language papers (not in the count)1
  1. [Structuring process approach to laparoscopic anatomical liver central lobectomy for hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status30
  1. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNot yet recruitingNCT07880106Lead sponsorStart 2026-10
  2. TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCCRecruitingNCT07658833Lead sponsorStart 2026-07
  3. Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06749678Lead sponsorN/AStart 2025-01
  4. Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II StudyRecruitingNCT07806292Lead sponsorPhase 2Start 2025-04
  5. FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingNCT06409637Lead sponsorPhase 1/Phase 2Start 2025-01
  6. Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaRecruitingNCT06581315Lead sponsorN/AStart 2024-08
  7. mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan CriteriaRecruitingNCT06607107Lead sponsorPhase 2Start 2024-02
  8. Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT06172205Lead sponsorPhase 3Start 2023-07
  9. Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver TransplantationRecruitingNCT05475613Lead sponsorPhase 2Start 2023-06
  10. Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy StrategyStatus unknownNCT06594289Lead sponsorN/AStart 2024-09
  11. Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft RejectionStatus unknownNCT05913583Lead sponsorStart 2023-04
  12. Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05924997Lead sponsorPhase 1/Phase 2Start 2023-07
  13. mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCStatus unknownNCT05412589Lead sponsorPhase 2Start 2022-06
  14. Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCCCompletedNCT06818097Lead sponsorStart 2021-10
  15. Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedNCT04962958Lead sponsorPhase 2Start 2021-12
  16. TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver CancerStatus unknownNCT05550025Lead sponsorPhase 2Start 2021-12
  17. Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver ResectionStatus unknownNCT02131441Lead sponsorN/AStart 2013-07
  18. Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCRecruitingNCT07267806Lead (inferred)Phase 3Start 2025-10
  19. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  20. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  21. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  22. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT05313282Study sitePhase 3Start 2022-06
  23. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Study sitePhase 2Start 2022-03
  24. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  25. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  26. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  28. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  29. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  30. Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular CarcinomaStatus unknownNCT02616926Study siteN/AStart 2015-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 11 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
11
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 3320242025: 112025

16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  2. Recruiting
    Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT05892289

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  3. Not yet recruiting
    Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT06365008

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  4. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  5. Not yet recruiting
    Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05890339

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  6. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryPeritoneal spread & advanced disease
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led11
  1. Clinicopathological characterization of gastric amphicrine carcinoma: A case series.2026Annals of diagnostic pathology
  2. Discovery of highly potent marine-derived compound Penicolinate H reveals SREBP-1 mediated lipogenesis as a druggable vulnerability in gastric cancer.2025Journal of translational medicineFree full text
  3. Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer.2024AgingFree full text
  4. A β-Galactosidase-Activated Fluorogenic Reporter for the Detection of Gastric Cancer In Vivo and in Urine.2024Analytical chemistry
  5. Artificial intelligence model for perigastric blood vessel recognition during laparoscopic radical gastrectomy with D2 lymphadenectomy in locally advanced gastric cancer.2024BJS openFree full text
  6. Marine fungus-derived alkaloid inhibits the growth and metastasis of gastric cancer via targeting mTORC1 signaling pathway.2023Chemico-biological interactions
  7. Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer.2022Cancer scienceFree full text
  8. Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer.2022Cell death & diseaseFree full text
  9. Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer.2022Current oncology (Toronto, Ont.)Free full text
  10. Nomogram for predicting mandatory ICU admission after gastrectomy for gastric cancer.2021Annals of palliative medicine
  11. Development and validation of a nomogram to predict intraoperative blood transfusion for gastric cancer surgery.2021Transfusion medicine (Oxford, England)RCT
Chinese-language papers (not in the count)1
  1. [Laparoscopy and endoscopy cooperative surgery in the treatment of stomach neoplasms].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status13
  1. Large Language Models Assist in Tumor MDTRecruitingNCT07504367Lead sponsorN/AStart 2026-01
  2. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNot yet recruitingNCT07880106Lead sponsorStart 2026-10
  3. Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric CancerNot yet recruitingNCT06365008Lead sponsorPhase 2Start 2026-06
  4. Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric CancerRecruitingNCT05892289Lead sponsorN/AStart 2024-06
  5. Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric CancerNot yet recruitingNCT05890339Lead sponsorN/AStart 2023-06
  6. Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort StudyCompletedNCT06897306Lead sponsorStart 2024-10
  7. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  8. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  9. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingStatus unknownNCT06036563Study siteStart 2023-09
  10. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  11. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  12. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  13. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 2 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Guangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 3320242025: 002025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led6
  1. HP1 enhances radio- and chemotherapy resistance in osteosarcoma via PARP1-dependent transcriptional repression and HR repair.2026Cancer letters
  2. SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.2024Cell death & disease
  3. AURKA inhibition induces Ewing's sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.2024Cell death & disease
  4. DNA Damage-Sensitized metal phenolic nanosynergists potentiate Low-Power phototherapy for osteosarcoma therapy.2024Journal of colloid and interface science
  5. ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells.2023Cell biology and toxicology
  6. IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells.2022Journal of translational medicine
Earlier papers (2016–2020)5
  1. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.2020Molecular cancer research : MCR
  2. Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma.2020Signal transduction and targeted therapy
  3. Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.2019Journal of cellular and molecular medicine
  4. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.2019Nucleic acids research
  5. Estrogen-related receptor α participates transforming growth factor-β (TGF-β) induced epithelial-mesenchymal transition of osteosarcoma cells.2017Cell adhesion & migration

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Guangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 8 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
8
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 2220242025: 002025

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06933394

    Age 18 months to 18 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPediatricsNeurology
Papers it led8
  1. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.2024BMC cancer
  2. Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition.2024Clinical and translational science
  3. Arsenic Trioxide inhibits Activation of Hedgehog Pathway in Human Neuroblastoma Cell Line SK-N-BE(2) Independent of Itraconazole.2023Anti-cancer agents in medicinal chemistry
  4. Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse.2023BMC cancer
  5. Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals.2023BMC pediatrics
  6. α-Synuclein Induces Neuroinflammation Injury through the IL6ST-AS/STAT3/HIF-1α Axis.2023International journal of molecular sciences
  7. Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  8. Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.2021Oncology research
Chinese-language papers (not in the count)2
  1. [A multicenter study of allogeneic hematopoietic stem cell transplantation for stage 4/M neuroblastoma].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Short-term results of a multicenter study based on a modified N7 induction regimen combined with arsenic trioxide in the treatment of children with high-risk neuroblastoma].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)6
  1. Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. α-synuclein accumulation in SH-SY5Y cell impairs autophagy in microglia by exosomes overloading miR-19a-3p.2019Epigenomics
  3. Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells.2018Biological research
  4. Analysis of treatment of large abdominal malignancies in children complicated with abdominal compartment syndrome: Report of six cases.2017Medicine
  5. Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy.2017Neurotoxicology
  6. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.2016International journal of oncology
All its trials on ClinicalTrials.gov, any status3
  1. Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaRecruitingNCT06933394Lead sponsorPhase 2Start 2025-05
  2. Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaNot yet recruitingNCT05303727Lead sponsorPhase 2Start 2022-08
  3. Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaActive, not recruitingNCT03503864Lead (inferred)Phase 2Start 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

9 hospitals in Guangzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantDrug combinations
Papers it led1
  1. The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis.2021Annals of palliative medicine
Chinese-language papers (not in the count)1
  1. [Plasmablastic plasma cell myeloma: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  3. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaStatus unknownNCT05422027Study sitePhase 1/Phase 2Start 2022-07
  4. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 002025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenMRD & relapse
Departments in papersMedical oncologyPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 4 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenDiagnosis & prognosisTreatment regimens
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 6 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.9%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 442025

23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    Phase
    Phase 1
    Started
    2024-01
    Registry
    NCT06465550

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai

  2. Recruiting
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    Phase
    Phase 2
    Started
    2019-11
    Registry
    NCT04143724

    Age 6 years to 17 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Papers it led6
  1. Clinical patterns of thalidomide in the treatment of transfusion-dependent β-thalassaemia in children: a prospective single-arm study in China.2025Annals of medicine
  2. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  3. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  4. Creating New Cis-Regulatory Elements of HBD to Reactivate Delta-Globin.2025Human gene therapy
  5. A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.2024Stem cell research & therapy
  6. Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major.2022Pediatric diabetes
Chinese-language papers (not in the count)2
  1. [Prevalence Rate and Risk Factors of Hypothyroidism in Children with Beta Thalassemia Major in Zhuhai Area].2021Zhongguo shi yan xue ye xue za zhi
  2. [Research Progress on Gene Therapy for β-thalassemia---Review].2021Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)5
  1. Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major.2019Clinical transplantation
  2. Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for β-thalassaemia major patients.2018Pediatric blood & cancer
  3. Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China.2018World journal of pediatrics : WJP
  4. [Clinical analysis of three cases with beta-thalassemia].2018Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. [Analysis of the influence of iron overload in glucose metabolism in thalassemia major patients].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status4
  1. Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing FactorsStatus unknownNCT06026839Lead sponsorStart 2023-10
  2. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  3. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  4. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruitingNCT05577312Study sitePhase 1/Phase 2Start 2022-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06541626

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  2. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 002025

2 hospitals in Guangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesPancreas & bile ductsLung & chest
Departments in papersGastroenterology / hepatologyENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Guangzhou for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led1
  1. Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.2023Frontiers in immunology
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 1120232024: 1120242025: 112025

20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05190848

    Age 16 years to 65 years (registered criteria)

    Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Guangzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

9 hospitals in Guangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07296458

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

  3. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学孙逸仙纪念医院

Sun Yat-sen Memorial Hospital

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Sun Yat-Sen Memorial Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital and Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital Affiliated to Sun Yat-sen University; Sun Yat-sen Memorial Hospitall; Sun Yatsen Memorial Hospital of Sun Yat-sen University; Second Affiliated Hospital of Sun Yat-sen

Suggest a correctionDownload the data